Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial

Conclusions: These results demonstrate that in pts with CD30-expressing rrPMBL, the combination of nivolumab and BV has a manageable safety profile and may provide a potential treatment option for this patient population.Study support: BMS. Writing support: Janice Zhou, Caudex, funded by BMS.Table.DisclosuresMoskowitz: Bristol Myers-Squibb: Consultancy, Research Funding; Merck: Research Funding; Incyte: Research Funding; Takeda: Honoraria; ADC Therapeutics: Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding. Cunningham: Roche pharmaceuticals: Research Funding. Barr: AbbVie, Gilead: Consultancy. Kline: iTeos: Research Funding; Merck: Honoraria, Research Funding. Kuruvilla: Gilead: Consultancy, Honoraria; Lundbeck: Honoraria; Celgene: Honoraria; BMS: Consultancy, Honoraria; Abbvie: Consultancy; Roche: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Merck: Consultancy, Honoraria; Karyopharm: Honoraria; Princess Margaret Cancer Foundation: Research Funding; Amgen: Honoraria; Leukemia and Lymphoma Society Canada: Research Funding; Seattle Genetics: Consultancy, Honoraria. Johnson: Lundbeck: Consultancy, Honoraria, Other: travel, Research Funding; Seattle Genetics: Honoraria; Merck: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria; AbbVie Inc.: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria, Other: travel, Research Funding. Mehta-Shah: Spectrum: Consultancy; Bristol-M...
Source: Blood - Category: Hematology Authors: Tags: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials: Poster I Source Type: research